| 000 | 01603 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250514225429.0 | ||
| 264 | 0 | _c20050816 | |
| 008 | 200508s 0 0 eng d | ||
| 022 | _a0344-5704 | ||
| 024 | 7 |
_a10.1007/s00280-004-0978-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWang, Hui | |
| 245 | 0 | 0 |
_aPreclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents. _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _cSep 2005 |
||
| 300 |
_a291-8 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntimycin A _xanalogs & derivatives |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacokinetics |
| 650 | 0 | 4 | _aChromatography, High Pressure Liquid |
| 650 | 0 | 4 | _aDogs |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 | _aDrug Stability |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aMicrosomes, Liver _xdrug effects |
| 650 | 0 | 4 | _aProtein Binding |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Inbred F344 |
| 650 | 0 | 4 | _aSpecies Specificity |
| 700 | 1 | _aLi, Mao | |
| 700 | 1 | _aRhie, Julie K | |
| 700 | 1 | _aHockenbery, David M | |
| 700 | 1 | _aCovey, Joseph M | |
| 700 | 1 | _aZhang, Ruiwen | |
| 700 | 1 | _aHill, Donald L | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 56 _gno. 3 _gp. 291-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00280-004-0978-8 _zAvailable from publisher's website |
| 999 |
_c15546872 _d15546872 |
||